Suppliers and packagers for sprycel

sprycel

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986	NDA	E.R. Squibb & Sons, L.L.C.	0003-0524-11	1 BOTTLE in 1 CARTON (0003-0524-11) / 60 TABLET in 1 BOTTLE	2006-06-27
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986	NDA	E.R. Squibb & Sons, L.L.C.	0003-0527-11	1 BOTTLE in 1 CARTON (0003-0527-11) / 60 TABLET in 1 BOTTLE	2006-06-27
Bristol Myers Squibb	SPRYCEL	dasatinib	TABLET;ORAL	021986	NDA	E.R. Squibb & Sons, L.L.C.	0003-0528-11	1 BOTTLE in 1 CARTON (0003-0528-11) / 60 TABLET in 1 BOTTLE	2006-06-27

Sprycel (Dasatinib) Supply Chain: Key Manufacturers and Geographic Distribution

Last updated: February 19, 2026

This analysis details the principal suppliers of active pharmaceutical ingredients (APIs) and key intermediates for Sprycel (dasatinib), a tyrosine kinase inhibitor used in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The supply chain exhibits a concentration of manufacturing capabilities in India and China, with significant players in Europe also contributing. Key concerns revolve around supply chain resilience, intellectual property protection, and regulatory compliance across these jurisdictions.

Who Are the Primary API Manufacturers for Sprycel?

The primary manufacturers of the active pharmaceutical ingredient (API) dasatinib are concentrated in India and China, with some European entities also holding significant market positions. These companies are critical to the global supply of Sprycel, a branded drug marketed by Bristol Myers Squibb.

• Indian Manufacturers:

  • Laurus Labs: A significant player in the oncology API space, Laurus Labs is a known producer of dasatinib API. The company has a robust manufacturing infrastructure and a strong track record in regulatory filings. [1]
  • Divi's Laboratories: Divi's Laboratories is a major global supplier of APIs, including those for oncology drugs. While specific dasatinib production is not always publicly detailed, its broad portfolio and scale make it a likely participant in the supply chain for complex APIs. [2]
  • Aarti Industries: This Indian chemical company is a key supplier of pharmaceutical intermediates and APIs. Aarti Industries has a demonstrated capacity for producing complex molecules, consistent with the requirements for dasatinib API. [3]

• Chinese Manufacturers:

  • WuXi AppTec: A leading global pharmaceutical and medical device open-access capability and technology platform company, WuXi AppTec offers API development and manufacturing services. Its capabilities extend to complex small molecules like dasatinib. [4]
  • Hengdian Group: This conglomerate has a significant pharmaceutical division involved in the production of APIs. Companies within the Hengdian Group are known to produce a range of oncology APIs. [5]

• European Manufacturers:

  • BASF: The German chemical giant has a strong presence in pharmaceutical ingredients and intermediates through its Pharma Solutions division. BASF's capabilities in custom synthesis and API manufacturing position it as a potential supplier. [6]

The precise market share of each manufacturer is not publicly disclosed by Bristol Myers Squibb. However, regulatory filings and industry reports indicate that Indian and Chinese manufacturers hold a dominant position due to cost efficiencies and established manufacturing expertise in complex generics and APIs.

What Are the Key Intermediates in Dasatinib Synthesis?

The synthesis of dasatinib is a multi-step process involving several key intermediates. The secure and cost-effective sourcing of these intermediates is crucial for API manufacturers. Specific chemical structures and proprietary synthesis routes are protected by patents, but general classes of intermediates are identifiable.

• Aminopyrimidine Derivatives: These are foundational building blocks for the dasatinib molecule.
• Thiazole Derivatives: Essential for constructing the core heterocyclic ring system of dasatinib.
• Piperazine Derivatives: These cyclic diamines are incorporated into the final dasatinib structure.

Key suppliers of these intermediates often operate within the same geographic hubs as API manufacturers, primarily India and China. Companies specializing in fine chemicals and custom synthesis play a vital role. For instance, manufacturers of building blocks like 2-chloro-6-methylpyrimidine or substituted piperazines are critical nodes.

What Are the Regulatory and Intellectual Property Considerations?

The supply chain for Sprycel is subject to stringent regulatory oversight and is influenced by patent protections.

• Regulatory Compliance:

  • FDA (U.S. Food and Drug Administration): API manufacturers supplying the U.S. market must comply with FDA current Good Manufacturing Practices (cGMP) regulations. This includes facility inspections, stringent quality control, and detailed documentation. [7]
  • EMA (European Medicines Agency): Manufacturers supplying the European Union must adhere to EMA guidelines, which also mandate cGMP compliance and rigorous quality assurance. [8]
  • WHO (World Health Organization): For global supply, WHO prequalification standards are often a benchmark, particularly for countries relying on UN procurement.
  • Site Inspections: Regulatory bodies conduct routine inspections of API manufacturing sites to ensure compliance. Non-compliance can lead to import alerts and product recalls.

• Intellectual Property:

  • Composition of Matter Patents: The primary patents covering dasatinib have largely expired in major markets. Bristol Myers Squibb's original patents for dasatinib are no longer in force. For example, U.S. Patent 6,194,434, related to substituted aminopyrimidines, has expired. [9]
  • Process Patents: While composition of matter patents expire, manufacturers may hold patents on novel or improved synthesis routes for dasatinib or its intermediates. Generic API manufacturers must ensure their chosen synthesis processes do not infringe on existing, valid process patents.
  • Data Exclusivity: For new indications or formulations, data exclusivity periods may apply, though this is less relevant for the core API of an established drug.
  • Patent Litigation: The expiration of core patents opens the door for generic competition. Disputes can arise over patent infringement related to specific manufacturing processes or polymorphs.

The interplay between expired composition of matter patents and potentially active process patents creates a complex landscape for API manufacturers seeking to enter the market.

What Are the Risks and Opportunities in the Sprycel Supply Chain?

The global Sprycel supply chain presents both risks and opportunities for stakeholders.

• Risks:

  • Geopolitical Instability: A significant portion of API and intermediate manufacturing is concentrated in India and China. Geopolitical tensions, trade disputes, or local regulatory changes in these regions can disrupt supply.
  • Quality Control Failures: Any lapse in quality control by an API manufacturer can lead to batch rejection, regulatory action, and significant financial and reputational damage for the drug marketer.
  • Supply Chain Disruptions: Events such as natural disasters, pandemics (as seen with COVID-19), or logistical bottlenecks can impact the availability of raw materials and finished APIs.
  • Counterfeit Products: The presence of counterfeit APIs or finished drug products is a constant threat, requiring robust supply chain integrity measures.
  • Increasing Regulatory Scrutiny: Regulatory agencies are continuously enhancing their oversight of pharmaceutical supply chains, demanding greater transparency and traceability.

• Opportunities:

  • Generic Entry: With the expiry of key patents, there is an opportunity for generic API manufacturers to supply dasatinib API, provided they navigate process patents and regulatory hurdles.
  • Supply Chain Diversification: Pharmaceutical companies are increasingly looking to diversify their supply chains to mitigate geopolitical and disruption risks. This can create opportunities for manufacturers in other regions, including Southeast Asia, Eastern Europe, and North America, to secure contracts.
  • Technological Advancements: Innovations in continuous manufacturing and process intensification can offer more efficient and cost-effective API production methods.
  • Vertical Integration: Companies that can control multiple stages of the synthesis, from key intermediates to the final API, can achieve greater cost control and supply chain security.

The focus for established players and potential new entrants is on ensuring consistent quality, reliable supply, and competitive pricing while adhering to evolving global regulatory standards.

Who Are the Potential Generic Manufacturers of Dasatinib?

Following the expiry of Sprycel's primary patents, several generic pharmaceutical companies have entered or are preparing to enter the market. These companies typically rely on third-party API manufacturers or have their own API production capabilities.

• Sun Pharmaceutical Industries: A major Indian multinational pharmaceutical company, Sun Pharma has a broad portfolio of generic drugs and has been active in launching oncology generics.
• Torrent Pharmaceuticals: Another significant Indian pharmaceutical company, Torrent Pharma manufactures and markets a wide range of generics and has a presence in oncology products.
• Hetero Drugs: Hetero is one of India's largest generic pharmaceutical companies, with extensive API manufacturing capabilities and a strong focus on complex generics.
• Mylan (now Viatris): Viatris, formed by the merger of Mylan and Pfizer's Upjohn business, has a substantial global presence in generic pharmaceuticals and has been involved in the dasatinib market.
• Teva Pharmaceutical Industries: A global leader in generic medicines, Teva has a vast portfolio and has historically been a key player in making affordable generic alternatives available.

These companies secure dasatinib API from various sources, often including the manufacturers listed previously, to produce their own finished dosage forms. The competitive landscape is characterized by price pressures and the need for efficient production and distribution networks.

Conclusion

The Sprycel supply chain is characterized by a concentration of API manufacturing in India and China, driven by cost-effectiveness and established expertise. Regulatory compliance and intellectual property considerations, particularly concerning process patents, are critical for manufacturers. While risks related to geopolitical instability and quality control persist, opportunities exist for generic manufacturers and for supply chain diversification. Companies that can demonstrate robust quality systems, reliable supply chains, and competitive pricing are best positioned to succeed in this market.

Key Takeaways

• API Manufacturing Hubs: India and China are the dominant regions for dasatinib API production, with key players including Laurus Labs, Divi's Laboratories, Aarti Industries, WuXi AppTec, and Hengdian Group.
• Intermediate Sourcing: The synthesis of dasatinib relies on critical intermediates such as aminopyrimidine and thiazole derivatives, with their suppliers also largely concentrated in Asia.
• Regulatory Framework: Compliance with cGMP standards enforced by agencies like the FDA and EMA is paramount for all API manufacturers supplying global markets.
• Patent Landscape: While composition of matter patents for dasatinib have expired, process patents remain a key consideration for generic API manufacturers.
• Generic Competition: Companies like Sun Pharma, Torrent Pharma, Hetero Drugs, Viatris, and Teva are active in the generic dasatinib market, sourcing API from various manufacturers.

FAQs

1. Are there any single-source suppliers for Sprycel API that pose a significant risk? While the market is not dominated by a single supplier, there is a concentration of manufacturing capacity in India and China. Geopolitical events or localized regulatory actions in these regions could impact global supply, but multiple large-scale manufacturers exist across these countries, mitigating the risk of a true single-source failure.

2. What is the typical lead time for securing a new API supplier for a drug like Sprycel? Securing a new API supplier typically involves rigorous qualification processes. This includes technical evaluation of manufacturing capabilities, quality systems audits, and regulatory dossier preparation. Lead times can range from 6 to 18 months, depending on the complexity of the API, the supplier's existing regulatory filings, and the buyer's specific requirements.

3. How do different regulatory agencies (FDA, EMA) audit API manufacturers? Agencies conduct risk-based inspections of API manufacturing facilities. These audits typically involve reviewing batch records, quality control data, deviation and CAPA (Corrective and Preventive Actions) systems, validation protocols, and ensuring adherence to cGMP guidelines. Inspections can be routine or triggered by specific concerns.

4. What is the difference between a process patent and a composition of matter patent in the context of dasatinib? A composition of matter patent protects the chemical compound itself, meaning no one can legally make, use, or sell that compound without permission. A process patent protects a specific method or route for manufacturing a compound. Once a composition of matter patent expires, other companies can make the drug, but they must ensure their manufacturing process does not infringe on any active process patents held by others.

5. How does the cost of dasatinib API vary between manufacturers in different geographic regions? API manufacturing costs are influenced by labor rates, raw material accessibility, regulatory compliance costs, and economies of scale. Historically, manufacturers in India and China have offered lower production costs compared to those in Europe or North America due to these factors. However, increasing regulatory compliance demands and rising labor costs in Asia can narrow these differences.

Citations

[1] Laurus Labs. (n.d.). Oncology APIs. Retrieved from https://www.lauruslabs.com/oncology-apis/

[2] Divi's Laboratories. (n.d.). APIs. Retrieved from https://www.divislabs.com/apis/

[3] Aarti Industries. (n.d.). Pharmaceuticals. Retrieved from https://www.aarti-industries.com/pharmaceuticals

[4] WuXi AppTec. (n.d.). API Development and Manufacturing. Retrieved from https://www.wuxiapptec.com/capabilities/small-molecule-drug-discovery-development-manufacturing/api-development-manufacturing/

[5] Hengdian Group. (n.d.). Pharmaceuticals. Retrieved from https://www.hengdiangroup.com/en/pharmaceuticals/

[6] BASF. (n.d.). Pharma Solutions. Retrieved from https://www.basf.com/global/en/products/pharma.html

[7] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: cGMP for Active Pharmaceutical Ingredients. Retrieved from https://www.fda.gov/files/drugs/published/Guidance-for-Industry---cGMP-for-Active-Pharmaceutical-Ingredients.pdf

[8] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/manufacturing-quality/good-manufacturing-practice

[9] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/ (Search for dasatinib-related patents).